The U.S. FDA has granted Novartis Pharmaceuticals Corporation marketing clearance for Exelon (rivastigmine tartrate) capsules, a cholinesterase inhibitor for the treatment of mild to moderate Alzheimer’s disease. Exelon therapy is proven effective in multiple phase III trials in the three key domains used to assess the disease — global functioning (including activities of daily living Read more about Alzheimer’s Treatment Granted FDA Approval[…]
SkyePharma PLC announced an agreement with Novartis Pharma AG to jointly develop a new product for the treatment of asthma and chronic obstructive pulmonary disease (COPD). The product will combine Novartis’ novel long-acting bronchodilator QAB149 with two SkyePharma technologies SkyeHaler(TM), a breath-activated multi-dose dry powder inhaler (MDDPI) device, to be marketed by Novartis as the Read more about Skyepharma Plans Joint Development With Novartis[…]
Transgenomic Inc. has entered into several specific agreements with Novartis Pharmaceuticals Corp. to provide mutation discovery services in the context of translational research programs in oncology. The goal is to support biomarker discovery efforts in the context of clinical trials by identifying genetic mutations that correlate with patients’ response(s) to cancer therapeutics. Transgenomic has performed Read more about Discovery Services Agreement For Novartis And Transgenomic[…]
Chiron has acquired exclusive worldwide development and commercialization rights to aerosolized cyclosporine (AcsA), an agent with potential in lung transplant acute rejection from Novartis. Clinical studies have been conducted in about 100 lung transplant patients at the University of Pittsburgh. Terms of agreement were not disclosed. Chiron Corporation, headquartered in Emeryville, California, has a strategic Read more about Chiron Licenses Acute Rejection Agent From Novartis[…]